Heron Therapeutics, Inc. (NASDAQ:HRTX)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group LLC in a report released on Wednesday. Jefferies Group also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.89) EPS, Q4 2017 earnings at ($0.96) EPS, FY2017 earnings at ($3.52) EPS, FY2018 earnings at ($2.28) EPS and FY2019 earnings at ($1.00) EPS.

Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $31.00 target price (up from $30.00) on shares of Heron Therapeutics in a report on Thursday, May 11th. ValuEngine raised shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. Cowen and Company reaffirmed a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Friday, May 26th. Aegis reaffirmed a “buy” rating and set a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. Finally, Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Two analysts have rated the stock with a sell rating and eleven have assigned a buy rating to the company. Heron Therapeutics has a consensus rating of “Buy” and a consensus target price of $31.00.

Shares of Heron Therapeutics (NASDAQ HRTX) remained flat at $15.25 during trading on Wednesday. 398,607 shares of the company were exchanged. The stock has a 50 day moving average of $15.54 and a 200-day moving average of $14.67. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $21.24.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million. On average, equities analysts expect that Heron Therapeutics will post ($3.50) EPS for the current fiscal year.

WARNING: “Heron Therapeutics’ (HRTX) “Buy” Rating Reiterated at Jefferies Group LLC” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/08/20/heron-therapeutics-hrtx-buy-rating-reiterated-at-jefferies-group-llc.html.

Large investors have recently made changes to their positions in the stock. Janus Henderson Group PLC purchased a new position in Heron Therapeutics during the second quarter worth approximately $78,134,000. Tang Capital Management LLC increased its position in Heron Therapeutics by 39.7% in the first quarter. Tang Capital Management LLC now owns 8,654,914 shares of the biotechnology company’s stock worth $129,824,000 after buying an additional 2,457,716 shares in the last quarter. FMR LLC increased its position in Heron Therapeutics by 36.7% in the first quarter. FMR LLC now owns 8,030,880 shares of the biotechnology company’s stock worth $120,464,000 after buying an additional 2,158,041 shares in the last quarter. Citadel Advisors LLC increased its position in Heron Therapeutics by 529.5% in the first quarter. Citadel Advisors LLC now owns 1,283,679 shares of the biotechnology company’s stock worth $19,255,000 after buying an additional 1,079,746 shares in the last quarter. Finally, Rubric Capital Management LP increased its position in Heron Therapeutics by 190.9% in the first quarter. Rubric Capital Management LP now owns 1,600,000 shares of the biotechnology company’s stock worth $24,000,000 after buying an additional 1,050,000 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.